© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Rifapentine didn't drop out of thin air; it traces its lineage to rifamycins, a class of antibiotics discovered in the late 1950s. Some smart folks working out of Milan isolated compounds from fermentation broths of Amycolatopsis mediterranei. They spotted something special in the rifamycin backbone—one core, plenty of potential. Chemists at Sanofi and Lederle explored structural tweaks, looking for a compound with a longer half-life and better performance. Rifapentine took shape in the 1970s as a semi-synthetic derivative, designed to improve on the limitations of rifampin. FDA approval came slowly, not until 1998 in the U.S., after long studies confirming its value in tuberculosis therapy, especially for those who couldn’t keep up with daily regimens.
You’ll see rifapentine as a strong antibiotic with a punchy spectrum, especially against Mycobacterium tuberculosis. Pharmaceutical suppliers offer it as tablets and powder, usually in doses up to 150 mg. Patients with latent tuberculosis infection, and some battling active disease, get rifapentine as part of a combination regimen. Folks in the lab know it under several generic and trade names—Priftin stands out on prescription pads in the United States.
If you poured rifapentine out of its bottle, you’d see an orange-red powder. Its chemical formula, C47H64N4O12, packs a considerable molecular weight of roughly 877 g/mol. Its structure features the naphthohydroquinone chromophore common to rifamycins, which provides those vivid colors and influences its reactivity. It doesn't dissolve readily in water; organic solvents like methanol or acetone work better. Store it protected from light and air, as this compound degrades under harsh conditions—especially in alkaline environments or with prolonged sunlight exposure.
Manufacturers standardize rifapentine for purity—usually more than 98% by HPLC. Look up a product certificate and you’ll see tests verifying identity (infrared spectroscopy and TLC), purity (chromatographic assays), and checks for heavy metals or specific impurities. Most drug labels advise storage below 25°C, away from children and pets. Expiration dates matter, since degraded rifapentine won’t deliver reliable treatment. The WHO and USP keep reference monographs available for labs running their own controls. Dosage forms come matched to clinical studies: typical regimens use 600 mg weekly dosing in adults, with advice on food and possible drug-drug interactions front and center.
Rifapentine production requires fermentation, followed by a cascade of chemical transformations. Industrial teams culture Amycolatopsis mediterranei strains under controlled pH and aeration to produce crude rifamycins. After extraction and purification steps, rifamycin SV stands out as a starting material. Chemists then roll up their sleeves for a multi-step synthetic sequence: they convert rifamycin SV to rifamycin S, oxidize to rifamycin O, then condense with a piperidine side chain under carefully controlled conditions. Crystallization yields pure rifapentine. Every batch feeds through filtration, washing, and vacuum drying before heading off for quality checks.
Rifapentine's structure cradles several functional groups ripe for manipulation. Chemical technicians can open or close rings, tweak side chains, or introduce substitutions at key spots. Hydrogenation under mild conditions alters the macrocyclic double bonds—a classic approach for making other rifamycins. The presence of a piperidyl group on the C25 position sets this drug apart from its cousin rifampin, boosting its half-life and lung penetration. Analytical chemists track every modification using HPLC and NMR, verifying batch-to-batch consistency. They know minor tweaks can swing pharmacokinetic data wildly, so every reaction step faces scrutiny.
No one wants confusion at the pharmacy counter—rifapentine comes with a short list of synonyms and trade names. “Priftin” covers the U.S. brand. Chemists sometimes call it Rifampicin Z, RPT, or by its full IUPAC moniker, though that one rarely leaves the lab. International listings stick to “rifapentine” or region-specific trade names depending on the market.
Handling rifapentine calls for caution. Direct contact with skin or eyes needs quick clean-up, and staff wear gloves and masks during compounding. Dust gets controlled with fume hoods and HEPA filtration in production plants. Tablets get packed in blister packs, not loose bags, to avoid light and moisture. Patients hear straight talk about the risk of liver toxicity, skin reactions, and possible interactions with anticonvulsants or antiretrovirals. Most health authorities, including the CDC and WHO, push for periodic monitoring of liver enzymes. Healthcare workers get briefed about spill procedures and safe disposal.
Rifapentine’s biggest role shows up in tuberculosis clinics. For latent TB infection, doctors prescribe it alongside isoniazid—the 3HP regimen is shorthand for 12 weeks of weekly therapy, a game-changer for adherence. Multidrug-resistant TB programs have also studied higher doses. Beyond TB, research pokes at its use against leprosy and other non-tuberculous mycobacteria, but evidence sits thinner here. Some veterinary applications exist, mostly in experimental models. Global health organizations highlight it as a tool for disease elimination, especially where daily pill regimens struggle to gain traction. Rural healthcare providers in high-burden countries rely on rifapentine’s weekly use to simplify logistics and cut drop-out rates.
Researchers keep pushing the boundaries with rifapentine. Recent studies target shorter TB treatment durations, high-dose regimens, and expanded use in HIV-positive populations. Pharmacologists track how rifapentine interacts with food, other infections, and genetic factors influencing drug breakdown. One big push involves finding pediatric-friendly formulations, since children metabolize drugs differently. Partnerships across universities, pharmaceutical companies, and global health agencies look for smarter drug combinations to tackle resistance. Advances in nanotechnology suggest new delivery systems might make the drug even more effective with fewer side effects.
Rifapentine isn’t a casual medication. Hepatotoxicity stays near the top of the risk list, especially if used alongside other drugs that stress the liver. Research in rodents and primates tracks dose-dependent changes, including oxidative injury and changes in liver enzyme profiles. Allergic reactions and rare blood disorders also make healthcare professionals cautious—routine lab checks and patient interviews stay standard. Carcinogenicity tests haven’t shown definitive links, but surveillance continues. Clinical trial data in humans highlights drug-drug interactions, especially with antiretrovirals and oral contraceptives, where rifapentine lowers the effectiveness by ramping up hepatic metabolism.
The next wave for rifapentine looks full of promise. Ongoing trials chase cures for not just tuberculosis, but other mycobacterial diseases. Simpler, shorter treatment courses attract public health advocates. The push for affordable generics and pediatric versions carries weight, especially in lower-income communities. As technology advances, new synthetic routes might deliver both greener production and higher yields. Digital health tools offer ways to monitor adherence and catch side effects early, giving both patients and clinicians more confidence. Expanded indications in leprosy or difficult lung infections could redefine the market. With multitasking antibiotics in short supply worldwide, rifapentine’s future will depend on how research keeps exploring uncharted territory while global health systems invest in access and safety.
Rifapentine plays a crucial role in the fight against tuberculosis (TB). TB remains a public health threat, making strong, reliable medicines like rifapentine more than just another option on the shelf. TB always seemed like an illness from another era to me until I learned that thousands across the world still struggle to get proper treatment. Rifapentine isn’t just another name in a pharmacy database—it’s a drug that gives people a better chance at recovery.
Doctors have turned to rifapentine for both active and latent TB. Its ability to stay in the bloodstream longer means people don’t need to take it as often as older antibiotics. Growing up, taking medicine every day felt like a huge chore, even for mild infections. Imagine keeping up with complex antibiotic schedules for months. Rifapentine changes that routine for TB patients—taking the load off with fewer doses per week. By simplifying the process, it helps make sure people don’t miss pills. Missing doses in TB treatment leads to dangerous drug resistance, which threatens everyone in the community.
People exposed to TB, but not yet sick, benefit from rifapentine as well. Preventive therapy stops TB from waking up in the body. Research published by the New England Journal of Medicine back in 2011 showed that a twelve-dose regimen with rifapentine and isoniazid worked as well as the traditional nine months with isoniazid alone. Those numbers mean fewer doctor visits and less pill fatigue, especially for folks living in remote areas.
Drug-resistant TB scares every infectious disease specialist. Once TB stops responding to regular medicines, treatment gets tougher, longer, and much more expensive. Rifapentine’s place in recommended combinations helps push back against these strains. The World Health Organization added rifapentine to its list of essential medicines after reviewing the benefits in modern treatment regimens.
Access remains a sticking point for countries where TB weighs heaviest. Supply chains are shaky in places wrestling with poverty or political unrest. I remember a friend from med school spending a year in rural southern Africa. She saw constant shortages of frontline drugs, even when supplies were promised. Rifapentine’s high price in some countries has also drawn criticism from advocacy groups like Médecins Sans Frontières. Generics could help bring down costs, but progress takes time and negotiation.
Policy shifts and funding changes can help close the gap. Local governments and global partnerships both play a part. Programs that focus on community health workers, outreach, and free medication drive up completion rates and drop TB transmission.
Rifapentine isn’t perfect, and like all medicines for tuberculosis, it can cause side effects including liver problems and allergic reactions. At the same time, its impact on reducing missed treatments stands out. Specialists and advocacy groups keep pushing for more clear guidelines and fair prices, hoping to make rifapentine available everywhere it’s needed. In the fight against TB, each improvement—like the shorter, simpler regimens rifapentine allows—means fewer families lose loved ones to a disease we know how to cure.
Rifapentine sits on the shelf alongside other antibiotics used for tuberculosis. It plays a big role, especially for people who need a long-term solution that’s easier to stick with than daily pills. Like most medicines, rifapentine comes with a few trade-offs. It’s tough on bacteria, but it can also bring some less-than-welcome side effects. Nobody wants extra headaches during treatment, so it’s helpful to know what could show up after starting a course of this drug.
Digestive problems show up often. Nausea, stomach pain, diarrhea, and loss of appetite can come on strong after a dose. Some folks say they taste something metallic or bitter, which can throw off normal eating. These symptoms usually ease up over time, but patients sometimes switch up meal routines just to keep things down.
The skin can react, too. Rashes bring itching or burning, and nobody likes finding unexpected bumps in the mirror. Mild skin changes clear up, but serious reactions need quick attention. Hives, swelling, or peeling skin puts the brakes on this drug right away. Serious signs mean calling a doctor, since rare but severe allergic reactions come as a real risk with most antibiotics.
Fatigue creeps in for some people. Energy drops, serving as an unwelcome companion to the other changes. It’s tough to pin fatigue on one cause—sometimes it stems from the infection, sometimes from the medicine, sometimes both. Still, tiredness stands out on the list of regular side effects, so it’s worth preparing for it at the start.
Some medicines add a splash of unexpected color to life, and rifapentine sits in that group. Urine, sweat, saliva, and tears can turn an orange-red shade. Folks often think something is terribly wrong until a pharmacist explains this is harmless and expected. It stains clothes and contact lenses, which brings a headache of its own, but it doesn't mean the medicine isn’t working.
The liver does most of the work breaking down rifapentine. Problems show up as dark urine, yellow skin, fatigue that won’t budge, or pain under the ribs. It’s rare but real. Blood tests during treatment keep an eye out for trouble before things get serious. Mixing rifapentine with alcohol piles on the risk, so doctors usually say no to happy hour until treatment wraps up.
People taking more than one medicine have even more to think about. Rifapentine speeds up how fast the body clears other drugs. Blood thinners, birth control, HIV medicines—these respond differently once rifapentine enters the mix. A pharmacist or doctor comes in handy for sorting out timing and possible dose changes.
Keeping open lines with a healthcare team sets people up for better outcomes. Quick reporting of changes, from a rash to stomach pain, beats waiting for problems to fix themselves. Getting the facts, sticking to check-ins, and avoiding risky combinations with other drugs go a long way. Real experiences teach us that heading off issues early opens the door to finishing treatment, beating the infection, and moving back into daily life with more confidence.
Rifapentine has become an important part of tuberculosis treatment plans around the world. I’ve seen firsthand how public health teams rally behind these antibiotics. People from all walks of life trust doctors to give them the straight facts. Here’s the challenge: getting every dose at the right time can make or break the fight against an infection as stubborn as tuberculosis.
Doctors and pharmacists do not hand out advice lightly. Rifapentine should be swallowed whole with food to cut down stomach aches. Skipping a meal can lead to nausea or cramps. Tuberculosis treatment already lasts months, so anything that helps someone stick with the plan makes a difference. Missing doses or splitting up pills without expert advice can lead to more resistant bacteria.
Confusion pops up often. Some people believe splitting up the day’s pills to spread the medicine out is better. In reality, the whole dose needs to hit the bloodstream at once to stay strong against bacteria. Combine that with regular food, and the medicine can do its job.
Rifapentine doesn’t work in a vacuum. Common medicines for diabetes, HIV, or epilepsy might tangle with it. New research notes how rifapentine speeds up the body’s processing of some other drugs. Blood levels of birth control pills or warfarin drop, so extra care is needed. A doctor should always check for possible clashes and adjust what someone takes alongside rifapentine.
Finishing a course of treatment shapes not only personal health but community health. Tuberculosis spreads quickly in close quarters, especially if someone feels healthy enough to drop medication early. The temptation to stop taking antibiotics once a person feels better is real—I’ve seen it play out with regular people who just want normal life back. The risk of incomplete treatment is drug-resistant tuberculosis. That beast is much harder to beat, so going all the way to the last pill counts.
Family support or check-in calls from nurses can turn the tide for someone trying to finish a tough treatment plan. Community clinics succeed when they teach tips for remembering pills—setting alarms, or pairing medicine times with daily meals. In some places, directly observed therapy steps in. This means a health worker watches each dose for certain periods. That approach lifts completion rates, especially in people with complicated schedules.
Supplies sometimes run low in remote regions. That can derail even the most dedicated patient. Health systems work best when they keep steady stocks and build trust through honest conversations. Explaining why a pill routine matters helps people buy in for the long haul.
No fancy words or silver bullets—just honest work. Sticking by the advice of nurses and doctors, trusting the science behind rifapentine, and reaching out for help when something feels off gives every person the best shot at recovery.
Rifapentine treats tuberculosis and acts as part of the powerful antibiotics called rifamycins. Tuberculosis doesn’t pause for pregnancy, so doctors often face a tough call. The stakes run high. Untreated tuberculosis brings real threats for mothers and newborns. Some people remember how their own families worried about infections. For people expecting a child or feeding one, every medication prompts a new layer of worry. Does the treatment fix a big problem, or does it open new doors of risk?
Rifapentine’s label doesn’t give a simple green or red light for pregnancy or breastfeeding. Large studies just aren’t there. Some data from animal studies suggest high doses can cause issues for growing embryos, but science always treads carefully before applying those results to people. In the few real-world reports available, negative birth outcomes haven’t appeared in big numbers. Still, missing numbers aren’t the same as proof of safety. You can ask any parent: absence of evidence never feels comforting with their baby in the balance.
Doctors and pharmacists share the same wish: protect moms and babies. The U.S. Centers for Disease Control and Prevention say to use rifapentine in pregnancy only if the danger of tuberculosis outweighs the uncertain risks. The World Health Organization gives similar counsel. When a woman’s risk of active tuberculosis stands high — maybe she lives in a place with stubborn outbreaks, or her immune system isn’t strong — her health team may still use rifapentine. Sometimes weighing these risks calls for family discussions that can feel as hard as the disease itself.
Rifapentine moves through breast milk in small amounts. At these low levels, babies haven’t shown clear side effects. Still, doctors encourage regular checkups for breastfed infants whose mothers take these drugs. If the baby develops jaundice or feeding trouble, action needs to be swift. Some clinics rely on regular lab tests or watch out for early signs of trouble. Parents might feel anxious, but good communication with a pediatrician goes a long way. Physicians often use experience from similar medicines to guide their advice, but they still wish for stronger evidence. Most parents would agree.
These gaps in knowledge stand out — and they matter. Government agencies and global health groups should fund better studies that follow mothers and babies, not just in high-income countries, but everywhere tuberculosis hits hard. Trust built on research brings peace of mind, and it raises health standards worldwide. Doctors also need guidance for complicated cases, not just the simplest scenarios. Many moms juggle multiple health demands or face social conditions that increase their tuberculosis risk. Nobody should feel left out because the research failed to reach them.
All patients deserve the right answers, especially at their most vulnerable moments. Good care doesn’t come from guesswork or slogans. It grows from respect for both the science and the people living with these decisions. Until new studies close the knowledge gap, health teams need honest conversations, strong monitoring, and plenty of empathy. Rifapentine can do a lot of good, but real-world choices count just as much as lab results.
Rifapentine belongs to a class of antibiotics known as rifamycins, meant to fight mycobacterial infections like tuberculosis (TB). What sets rifapentine apart from other drugs? Its weekly dosing helps make TB treatment less of a daily challenge. My experience with folks taking rifapentine—some with long medication lists—taught me just how careful the process needs to be. Rifapentine interacts with many other drugs, sometimes in subtle ways that can lead to big problems down the line.
This isn’t a hidden risk. Drugs like rifapentine change how the liver breaks down other medicines. Rifapentine gets the liver going, ramping up enzymes called cytochrome P450s. Think of the liver as a sorting station for medicines; if rifapentine makes those workers go faster, any drug passing through might get broken down too quickly. Blood levels drop. Suddenly, that heart medicine or birth control isn’t working as well as expected. There’s evidence—studies in Clinical Infectious Diseases and the CDC—that confirm this impact.
One area where the real world smacks you in the face: oral contraceptives. I’ve seen patients shocked at unexpected pregnancies because rifapentine lowered the hormone levels in their system. Rifapentine speeds metabolism of estrogen and progestin, so those pills offer less protection. Official recommendations say women should use another form of birth control—preferably non-hormonal—if taking rifapentine.
Rifapentine dulls the action of warfarin, a popular blood thinner. Blood clots then become a bigger risk. Monitoring these patients isn’t optional—it’s required. The same goes for newer anticoagulants, since nobody can predict exactly how fast the liver will chew through them. Not every clinic catches this in time, and sometimes the first sign is a complication, not a lab value.
Antiretroviral drugs, used by people with HIV, also tangle with rifapentine. The worry? Poorer control of HIV. Some newer drugs, like integrase inhibitors, respond just as unpredictably as the older protease inhibitors. Anti-seizure drugs like phenytoin or carbamazepine become even more unpredictable with rifapentine in the mix—sometimes causing seizures to break through, despite months of stable control.
Rifapentine mixes problems into treatments for diabetes (some drugs become less effective), fungal infections (lower levels of antifungal drugs), and even heart rhythm problems. Grapefruit juice and St. John's Wort, often consumed without thinking they count as medication, also make things worse. I’ve seen patients taking strong herbal supplements interact with rifapentine, turning a standard TB therapy into a risky routine.
All these interactions highlight the need for thorough medication review. Patients and providers who share medication details, including supplements and herbal remedies, reduce the risk of surprises. Pharmacists play a crucial role, often catching things missed in a busy clinic. Switching to alternatives, spacing out doses, or picking different antibiotics sometimes prevent major trouble. Technology does help, but nothing beats honest conversations and a careful eye. Keeping every doctor, nurse, and pharmacist in the loop means no one has to wonder about a pill’s effect on another.
| Names | |
| Preferred IUPAC name | (7S,9E,11S,12R,13S,14R,15R,16S,17Z,19Z)-11,12,13,14,15,16-hexahydroxy-7-methoxy-2,4,12,14,17,19,21-heptamethyl-23-oxa-4,7,13,15,21-pentaazabicyclo[19.3.1]hexacosa-1(25),2,4,9,17,19,21-heptaene-3,10,18-trione |
| Other names |
Priftin |
| Pronunciation | /ˌrɪfəˈpɛntaɪn/ |
| Identifiers | |
| CAS Number | 61379-65-5 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Rifapentine**: `C[C@@H]1C(=O)c2c(O)ccc(O)c2C(=O)C1(C)C=C(C)C=C(C)C(=O)OC12C(C(=O)O)=C(C)C(O)CC(C)(O)C(O)C1(C)CCC(O)C2(O)C(=O)C(C)CC(O)=O` |
| Beilstein Reference | 4140063 |
| ChEBI | CHEBI:45086 |
| ChEMBL | CHEMBL1200962 |
| ChemSpider | 21735698 |
| DrugBank | DB01145 |
| ECHA InfoCard | 100.116.865 |
| EC Number | EC 6.3.2.27 |
| Gmelin Reference | 112859 |
| KEGG | D08316 |
| MeSH | D018927 |
| PubChem CID | 5381226 |
| RTECS number | VW2070000 |
| UNII | Z82A2V61YN |
| UN number | UN3248 |
| CompTox Dashboard (EPA) | DTXSID8071471 |
| Properties | |
| Chemical formula | C47H64N4O12 |
| Molar mass | 877.039 g/mol |
| Appearance | Orange-red crystalline powder |
| Odor | Odorless |
| Density | 1.4 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 3.9 |
| Vapor pressure | 9.43E-15 mm Hg |
| Acidity (pKa) | 4.2 |
| Basicity (pKb) | 6.07 |
| Magnetic susceptibility (χ) | -64.2×10^-6 cm³/mol |
| Refractive index (nD) | 1.752 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.07 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 302.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -6937 kJ/mol |
| Pharmacology | |
| ATC code | J04AB05 |
| Hazards | |
| Main hazards | May cause allergic skin reaction, may cause respiratory irritation, suspected of causing cancer |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GH, R, F |
| Signal word | Warning |
| Hazard statements | H302, H350 |
| Precautionary statements | Keep out of reach of children. For professional use only. Use with adequate ventilation. Avoid contact with eyes, skin and clothing. In case of contact, immediately flush with plenty of water. If swallowed, get medical help immediately. |
| Flash point | Flash point: >110°C |
| Lethal dose or concentration | LD50 oral rat: >1,500 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse, oral: 1750 mg/kg |
| NIOSH | RX8575000 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 600 mg once daily |
| Related compounds | |
| Related compounds |
Rifampicin Rifabutin Rifalazil |
